Explore › Finding
Finding decline
Patients who received >=2 cycles of bridging chemotherapy had significantly lower overall survival compared to those who received 1 cycle (HR 3.73, 95% CI: 1.39-9.97, p=0.006), with death from disease progression occurring in 62.5% of the >=2 cycles group versus 15.8% in the 1 cycle group.
Effect sizeHR 3.73
CI95% CI: 1.39-9.97
Comparator1 cycle of bridging chemotherapy prior to CD19-specific CAR T cell infusion
Effect summarydecline; HR 3.73; CI: 95% CI: 1.39-9.97
Adverse eventsgrade ≥ 3 infection 94% versus 56%

Connected entities

Interventions
bridging chemotherapy
Conditions
Precursor B-cell acute lymphoblastic leukemia in remission
Outcomes
overall survival

Source

PMC9361393
Impact of Bridging Chemotherapy on Clinical Outcomes of CD19-Specific CAR T Cell Therapy in Children/Young Adults with Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia
Read on PMC → · View in graph →